Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Besses

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
International Journal of Clinical Pharmacology and Therapeutics|September 5, 2012
Pharmacokinetics and tolerability of anagrelide hydrochloride in young (18 - 50 years) and elderly (≥ 65 years) patients with essential thrombocythemiaCarlos Besses, Wolfgang Zeller, Alberto Alvarez-Larrán, et al.
European Journal of Haematology|March 27, 2015
Masked polycythaemia vera: presenting features, response to treatment and clinical outcomesAlberto Alvarez-Larrán, Anna Angona, Agueda Ancochea, et al.
Leukemia Research|December 4, 2012
Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS studyCarlos Besses, Jean-Jacques Kiladjian, Martin Griesshammer, et al.
Haematologica|June 13, 2012
Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemiaAlberto Alvarez-Larrán, Agueda Ancochea, Anna Angona, et al.
Haematologica|December 17, 2013
Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety studyLuigi Gugliotta, Carlos Besses, Martin Griesshammer, et al.
British Journal of Haematology|January 12, 2011
Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patientsCarlos Besses, Alberto Alvarez-Larrán, Luz Martínez-Avilés, et al.
Haematologica|October 29, 2017
Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety studyGunnar Birgegård, Carlos Besses, Martin Griesshammer, et al.
Leukemia & Lymphoma|September 4, 2008
Persistent monoclonality after histological remission in gastric mucosa-associated lymphoid tissue lymphoma treated with chemotherapy and/or surgery: influence of t(11;18)(q21;q21)Almudena Santón, Mónica García-Cosio, Beatriz Bellosillo, et al.
Cancers|January 30, 2021
Polycythemia Vera and Essential Thrombocythemia Patients Exhibit Unique Serum Metabolic Profiles Compared to Healthy Individuals and Secondary Thrombocytosis PatientsNuria Gómez-Cebrián, Ayelén Rojas-Benedicto, Arturo Albors-Vaquer, et al.
Annals of Hematology|January 25, 2019
Study of the frequency and reasons for discontinuation of different lines of treatment in patients with multiple myelomaAlicia Senín, Francesc García-Pallarols, Randa Ben Azaiz, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
International Journal of Clinical Pharmacology and Therapeutics|September 5, 2012
Pharmacokinetics and tolerability of anagrelide hydrochloride in young (18 - 50 years) and elderly (≥ 65 years) patients with essential thrombocythemiaCarlos Besses, Wolfgang Zeller, Alberto Alvarez-Larrán, et al.
European Journal of Haematology|March 27, 2015
Masked polycythaemia vera: presenting features, response to treatment and clinical outcomesAlberto Alvarez-Larrán, Anna Angona, Agueda Ancochea, et al.
Leukemia Research|December 4, 2012
Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS studyCarlos Besses, Jean-Jacques Kiladjian, Martin Griesshammer, et al.
Haematologica|June 13, 2012
Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemiaAlberto Alvarez-Larrán, Agueda Ancochea, Anna Angona, et al.
Haematologica|December 17, 2013
Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety studyLuigi Gugliotta, Carlos Besses, Martin Griesshammer, et al.
British Journal of Haematology|January 12, 2011
Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patientsCarlos Besses, Alberto Alvarez-Larrán, Luz Martínez-Avilés, et al.
Haematologica|October 29, 2017
Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety studyGunnar Birgegård, Carlos Besses, Martin Griesshammer, et al.
Leukemia & Lymphoma|September 4, 2008
Persistent monoclonality after histological remission in gastric mucosa-associated lymphoid tissue lymphoma treated with chemotherapy and/or surgery: influence of t(11;18)(q21;q21)Almudena Santón, Mónica García-Cosio, Beatriz Bellosillo, et al.
Cancers|January 30, 2021
Polycythemia Vera and Essential Thrombocythemia Patients Exhibit Unique Serum Metabolic Profiles Compared to Healthy Individuals and Secondary Thrombocytosis PatientsNuria Gómez-Cebrián, Ayelén Rojas-Benedicto, Arturo Albors-Vaquer, et al.
Annals of Hematology|January 25, 2019
Study of the frequency and reasons for discontinuation of different lines of treatment in patients with multiple myelomaAlicia Senín, Francesc García-Pallarols, Randa Ben Azaiz, et al.
Pageof 5